DGIdb - NATEGLINIDE Drug Record

NATEGLINIDE chembl:CHEMBL783 Approved

Alternate Names:

A-4166
DJN-608
SDZ DJN 608
AY-4166
STARSIS
STARLIX
SDZ-DJN-608
NATEGLINIDE
(-)-N-(TRANS-4-ISOPROPYLCYCLOHEXANECARBONYL)-D-PHENYLALANINE
AY 4166
A 4166
AY4166
DJN608
STARLIX®
TRANS-N-{[4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL}-D-PHENYLALANINE
chembl:CHEMBL783
drugbank:00731
pubchem.compound:60026
chemidplus:105816-04-4
rxcui:274332

Drug Info:

Year of Approval	2000
Drug Class	hypoglycemic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidiabetic

(3 More Sources)

Publications:

Kalliokoski A et al., 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide., J Clin Pharmacol
Hu et al., 2000, Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide., J. Pharmacol. Exp. Ther.
Chachin et al., 2003, Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels., J. Pharmacol. Exp. Ther.
Hansen et al., 2002, Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1., Diabetes
Sunaga et al., 2001, The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide., Eur. J. Pharmacol.
Norman et al., 2001, Nateglinide: A structurally novel, short-acting, hypoglycemic agent., Drugs Today
Dornhorst, 2001, Insulinotropic meglitinide analogues., Lancet
Cheng Y et al., 2013, Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers., Eur J Clin Pharmacol
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

NATEGLINIDE ABCC8

Interaction Score: 2.91

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Trial Name Starlix

PMIDs:
10773014 12604678 12196472 11716850 12764427 11728565

Sources:
TdgClinicalTrial ChemblInteractions
NATEGLINIDE KCNJ1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
NATEGLINIDE KCNJ11

Interaction Score: 0.44

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TEND
NATEGLINIDE CALCA

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NATEGLINIDE SLCO1B1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18187595

Sources:
PharmGKB
NATEGLINIDE CYP2C9

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22842957 22931300

Sources:
DTC PharmGKB
NATEGLINIDE CYP2C19

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
NATEGLINIDE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
NATEGLINIDE CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
NATEGLINIDE CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB

TdgClinicalTrial: NATEGLINIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Publications:
TEND: NATEGLINIDE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class hypoglycemic agents

Year of Approval 2000

Publications:
DTC: NATEGLINIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL783 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: nateglinide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Cheng Y et al., 2013, Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers., Eur J Clin Pharmacol

Kalliokoski A et al., 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide., J Clin Pharmacol

TTD: Nateglinide
- Version: 2020.06.01
Alternate Names:

D06PSS TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL783
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL783
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Sulfonylurea receptor 1, Kir6.2 blocker
Trial Name	Starlix

blocker (inhibitory)
inhibitor (inhibitory)

NATEGLINIDE Drug Record

NATEGLINIDE chembl:CHEMBL783 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker Trial Name Starlix

PMIDs: 10773014 12604678 12196472 11716850 12764427 11728565

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TEND

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18187595

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22842957 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC PharmGKB

TdgClinicalTrial: NATEGLINIDE

Alternate Names:

Drug Info: Drug Indications antidiabetic Drug Class Small Molecule FDA Approval approved

Publications:

TEND: NATEGLINIDE

Alternate Names:

Drug Info: Drug Class hypoglycemic agents Year of Approval 2000

Publications:

DTC: NATEGLINIDE

Alternate Names: CHEMBL783 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: nateglinide

Alternate Names:

Drug Info:

TTD: Nateglinide

Alternate Names: D06PSS TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL783

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL783

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Trial Name Starlix

PMIDs:
10773014 12604678 12196472 11716850 12764427 11728565

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
18187595

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22842957 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC PharmGKB

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Drug Info:

Drug Class hypoglycemic agents

Year of Approval 2000

Alternate Names:

CHEMBL783 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D06PSS TTD Drug ID